Theriva Biologics is a Rockville clinical-stage oncology shop whose equity now prices as a near-cash call on a stroma-degrading oncolytic adenovirus, not as a funded late-stage franchise. The second-quarter print converts earlier FDA and EMA alignment into a tiny dosing study rather than a financed registrational program. First patients are now on VIRAGE2, a small Spanish protocol that tests more frequent dosing of the lead virus on top of gemcitabine and nab-paclitaxel. The cohort is sized at six evaluable patients. That is real progress on the science and a confession on the balance sheet: the company can afford a proof-of-concept cohort, not the Phase 3 design regulators have already discussed.
Cash at mid-year sat just above $11 million. The balance had already slipped to $9.6 million by early August. The accumulated deficit now exceeds $364 million. Management states the cash funds operations into the first quarter of next year, but only for limited clinical, regulatory, and manufacturing work. A September workforce reduction is expected to save about $1.8 million a year. The market capitalization hovers near the cash pile, which means almost no option value is being assigned to the completed pancreatic study, the retinoblastoma protocol, or the published head-and-neck data.
The debate is no longer whether the lead virus showed a survival signal in metastatic pancreatic cancer. The completed mid-stage study produced a median overall survival of 10.8 months on the virus plus chemotherapy. Chemotherapy alone delivered 8.6 months. The hazard ratio was 0.57. What remains unresolved is who pays for the next experiment. Without a partner, a merger, or a much larger equity raise, the registrational path stays theoretical while the at-the-market facility and out-of-the-money warrants keep expanding the share count.